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Abstract: Oxidative stress is implicated in the pathogenesis of many diseases, including 
serious ocular diseases, keratoconus (KC) and Fuchs endothelial corneal dystrophy (FECD). 
Flap endonuclease 1 (FEN1) plays an important role in the repair of oxidative DNA damage 
in the base excision repair pathway. We determined the association between two single 
nucleotide polymorphisms (SNPs), c.–441G>A (rs174538) and g.61564299G>T (rs4246215), 
in the FEN1 gene and the occurrence of KC and FECD. This study involved 279 patients 
with KC, 225 patients with FECD and 322 control individuals. Polymerase chain 
reaction (PCR) and length polymorphism restriction fragment analysis (RFLP) were 
applied. The T/T genotype of the g.61564299G>T polymorphism was associated with an 
increased occurrence of KC and FECD. There was no association between the c.–441G>A 
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polymorphism and either disease. However, the GG haplotype of both polymorphisms was 
observed more frequently and the GT haplotype less frequently in the KC group than the 
control. The AG haplotype was associated with increased FECD occurrence. Our findings 
suggest that the g.61564299G>T and c.–441G>A polymorphisms in the FEN1 gene may 
modulate the risk of keratoconus and Fuchs endothelial corneal dystrophy. 
Keywords: keratoconus; Fuchs endothelial corneal dystrophy; flap endonuclease 1;  
DNA repair 
 
1. Introduction 
As an outer layer of the eye, the cornea is especially susceptible to environmental factors. Exposure 
to blue light and ultraviolet (UV) radiation, as well as mechanical trauma, resulting from chronic eye 
rubbing and contact lens wearing, may produce reactive oxygen species (ROS) and induce oxidative 
stress in it [1]. Oxidative stress is implicated in the pathogenesis of several ocular diseases, including 
keratoconus (KC) and Fuchs endothelial corneal dystrophy (FECD) [2,3]. 
Keratoconus is a degenerative disorder of the eye, characterized by a progressive thinning of the 
corneal stroma and loss of normal corneal architecture, which assumes a conical shape [4]. Other signs 
include breaks in Bowman’s membrane, deposition of iron in the basal layers of the corneal epithelium 
and the formation of fine parallel lines in the posterior stroma [5]. Keratoconus typically occurs at 
puberty and progresses until the third or fourth decade of life. Clinical signs differ depending on the 
stage of the disease [4,5]. In the early cases, KC is asymptomatic; however, further development leads 
to a distortion of vision and image blurring [6,7]. A prevalence of KC ranges from 1.3 to 25 per 
100,000 in the general population [8,9]. Despite numerous investigations, the aetiology of KC is  
not completely understood. It is suspected that multiple genes together with environmental factors 
contribute to its pathogenesis [10]. Although KC is usually a sporadic disease, in some cases, 
autosomal dominant inheritance was noticed. Prevalence of KC in first degree relatives is 15–67-times 
higher than in the general population, indicating the importance of the genetic trait in its aetiology [9]. 
A genetic basis for KC is also supported by high concordance in monozygotic twins [11,12]. Several 
genes were proposed as candidate genes for KC, including different types of collagen (COL4A3 and 
COL4A4), proteinase inhibitors (TIMP3), as well as antioxidant genes (SOD1) and genes belonging  
to the homeobox family (VSX1) [13–15]. Moreover, linkage studies carried out in families affected  
by KC detected chromosomal loci associated with this disease, including: 3p14-q13; 5q14-q21;  
15q22-q24; 1p36; 8q13-q21, 2p24; 16q22-q23; 13q32; and 20q12 [16–23]. However, few causative 
mutations were identified in these regions. 
FECD is a disorder of corneal endothelium. This disease is characterized by a decrease in endothelial 
cell density, deposition of Descemet’s membrane, termed guttae, and changes in endothelial cell 
morphology [24,25]. The loss of corneal endothelial cells causes a disturbance of the fluid balance in 
this tissue, which results in decreased visual acuity. FECD brings on blurred vision, which progresses 
as the disease progresses, and in the late stages, it can cause blindness [26]. The prevalence of FECD 
in individuals over 40 is approximately 4% [27]. Currently, corneal transplantation is the only treatment 
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modality to restore lost vision [28]. FECD is a common cause of corneal transplantation in the United 
States for patients over 60 [28,29]. The pathogenesis of this disease is complex and results from the 
interaction between genetic and environment factors [3,28]. The disorder is classified into two forms: 
early and late onset [30]. The early-onset form is rare and begins in early middle age. This form is 
linked with mutations in COL8A2, which encodes the collagen helix domain of the α2 chain of type 
VIII collagen, a main component of Descemet’s membrane [31,32]. The late-onset FECD is more 
common and typically appears in the fifth decade of life [26]. To date, three genes, ZEB1 (TCF8), 
encoding the zinc finger E-box-binding homeobox 1 transcription factor, SLC4A11, coding for  
a sodium-borate cotransporter, and LOXHD1, encoding lipoxygenase homology domain 1 were found 
to be involved in the development of more common late-onset FECD [33–35]. In addition, several 
chromosomal loci were associated with late-onset FECD, including FCD1 at 13pTel-13q12.13, 
FCD2 at 18q21.2-q21.32, FCD3 described at 5q33.1-q35.2 and FCD4 at 9p24.1e22.1 [34,36–39].  
A linkage study also identified chromosomes 1, 7, 15, 17 and X as potentially involved in the 
development of FECD [38]. 
Genetic factors in KC and FECD were intensively investigated in recent years [9,28,40,41]. In this 
work, we checked whether polymorphisms of the flap endonuclease 1 (FEN1) gene may be associated 
with KC or FECD occurrence. FEN1 plays an essential role in the repair DNA damage during  
long-patch base-excision repair (BER), so changes in its gene may lead to the increased susceptibility 
of DNA to oxidative injury. The results of several studies indicate a role for oxidative stress in the 
development of KC and FECD. We hypothesize that the variability in the FEN1 gene may change the 
susceptibility to oxidative stress and contribute to the development of KC and FECD. To verify this 
hypothesis, we checked the association between the c.–441G>A (rs174538) and g.61564299G>T 
(rs4246215) polymorphisms and KC/FECD occurrence, as well as the modulation of this association 
by some demographic and risk factors for KC/FECD. 
2. Results 
2.1. Characteristics of Study Subjects 
Demographic variables and potential risk factors for KC and FECD of the study patients and 
controls are shown in Table 1. There were significantly more subjects with a positive family history for 
KC and FECD (first degree relatives) among the patients in comparison to controls (11% and 16% vs. 
3%, p < 0.001). We showed a significant differences between the distribution of family history for 
KC/FECD (positive vs. negative family history) and co-occurrence of visual impairment (yes vs. no) 
among KC/FECD patients and controls. We also demonstrated a significant differences between the 
distribution of allergies (yes vs. never) and heart or vascular diseases (yes vs. never) and co-occurrence 
of visual impairment (yes vs. no) among KC patients and controls. These parameters were further 
adjusted in a multivariate logistic regression model for possible confounding factors of the main effect 
of the single nucleotide polymorphisms (SNPs). 
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Table 1. Characteristics of keratoconus (KC) and Fuchs endothelial corneal dystrophy (FECD) 
patients and controls enrolled in this study. 
Feature 
Controls (n = 322) KC (n = 279) 
p 
FECD (n = 225) 
p 
Number Frequency Number Frequency Number Frequency 
Sex 
Females 205 0.64 84 0.30 <0.001 172 0.76 0.002 
Males 117 0.36 195 0.70  53 0.24  
Age 
Mean ± SD 
63.78 ± 
18.82 
 
36.33 ± 
12.08 
 <0.001 * 
70.52 ± 
9.81 
 <0.001 * 
Range 19–100  14–68   37–91   
Smoking 
Yes 
(current/former) 
107 0.33 88 0.32 0.724 78 0.35 0.797 
Never 215 0.67 191 0.68  147 0.65  
KC/FECD in family 
Yes 9 0.03 31 0.11 0.001 36 0.16 <0.001 
No 313 0.97 248 0.89  189 0.84  
BMI 
≤25 130 0.41 127 0.45 0.469 93 0.41 0.939 
25–30 114 0.35 91 0.33  77 0.34  
≥30 78 0.24 61 0.22  55 0.25  
Visual impairment 
Yes 103 0.32 195 0.70 <0.001 123 0.55 <0.001 
No 219 0.68 84 0.30  102 0.44  
Allergies 
Yes 40 0.12 77 0.28 <0.001 40 0.18 0.105 
No 282 0.88 202 0.72  185 0.82  
Heart and vascular diseases 
Yes 177 0.55 58 0.21 <0.001 130 0.58 0.573 
No 145 0.45 221 0.79  95 0.42  
p-values for two-sided χ2 test, except: * p-values for t-test; and p < 0.05 are in bold. 
2.2. Relationship between Age, Sex, Tobacco Smoking, Co-Occurrence of Visual Disturbances, BMI, 
Heart and Vascular Diseases, Allergies and KC/FECD in Family and the Risk of KC/FECD 
Independent of Genotype 
We analysed the relationships between age, sex, tobacco smoking, co-occurrence of visual 
disturbances, body mass index (BMI), heart and vascular diseases, allergies and KC/FECD in family 
and the risk of KC/FECD independently of genotype. We compared KC and FECD patients with 
controls according to these parameters (Tables 2 and 3). Male sex, KC in family, co-occurrence of 
visual disturbances and allergies significantly increased the occurrence of KC, whereas age and  
co-occurrence of heart and vascular diseases decreased this occurrence. We also found that female 
sex, age, FECD in family and co-existence of visual disturbances significantly increased the 
occurrence of FECD. 
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Table 2. Risk of KC associated with age, sex, tobacco smoking, co-occurrence of  
visual disturbances, body mass index (BMI), heart and vascular diseases, allergies and 
family history of keratoconus (KC). 
Characteristics 
Controls KC 
OR (95% CI) p 
Number Frequency Number Frequency 
Sex       
Females 205 0.64 84 0.30 0.25 (0.17–0.35) <0.001 
Males 117 0.36 195 0.70 4.07 (2.89–5.72) <0.001 
Age 63.78 ± 18.82  36.33 ± 12.08  0.91 (0.90–0.93) <0.001 
Smoking 
Yes (current/former) 107 0.33 88 0.32 0.94 (0.66–1.32) 0.710 
Never 215 0.67 191 0.68 1.07 (0.76–1.50) 0.710 
KC in family 
Yes 6 0.02 31 0.11 6.52 (2.68–15.89) <0.001 
No 316 0.98 248 0.89 0.15 (0.06–0.37) <0.001 
BMI 
≤25 130 0.41 127 0.45 1.23 (0.89–1.70) 0.219 
25–30 114 0.35 91 0.33 0.88 (0.63–1.24) 0.470 
≥30 78 0.24 61 0.22 0.88 (0.60–1.30) 0.529 
Visual impairment 
Yes 103 0.32 195 0.70 4.87 (3.43–6.91) <0.001 
No 219 0.68 84 0.30 0.20 (0.14–0.29) <0.001 
Allergies 
Yes 40 0.12 77 0.28 2.62 (1.72–3.99) <0.001 
No 282 0.88 202 0.72 0.38 (0.25–0.58) <0.001 
Heart and vascular diseases 
Yes 177 0.55 58 0.21 0.22 (0.15–0.31) <0.001 
No 145 0.45 221 0.79 4.63 (3.22–6.66) <0.001 
OR, odds ratio; 95% CI, 95% confidence interval; p-values < 0.05 along with corresponding ORs are in bold. 
Table 3. Risk of Fuchs endothelial corneal dystrophy (FECD) associated with age, sex, 
tobacco smoking, co-occurrence of visual disturbances, body mass index (BMI), heart and 
vascular diseases, allergies and family history of FECD. 
Characteristics 
Controls FECD 
OR (95% CI) p 
Number Frequency Number Frequency 
Sex 
Females 205 0.64 172 0.76 1.85 (1.26–2.71) 0.002 
Males 117 0.36 53 0.24 0.54 (0.37–0.79) 0.002 
Age 63.78 ± 18.82  70.52 ± 9.81  1.03 (1.01–1.04) <0.001 
Smoking 
Yes (current/former) 107 0.33 78 0.35 1.08 (0.75–1.55) 0.682 
Never 215 0.67 147 0.65 0.93 (0.65–1.33) 0.682 
FECD in family 
Yes 3 0.01 36 0.16 20.54 (6.24–67.65) <0.001 
No 319 0.99 189 0.84 0.04 (0.01–0.16) <0.001 
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Table 3. Cont. 
Characteristics 
Controls FECD 
OR (95% CI) p 
Number Frequency Number Frequency 
BMI 
≤25 130 0.41 93 0.41 1.04 (0.73–1.47) 0.827 
25–30 114 0.35 77 0.34 0.94 (0.65–1.34) 0.724 
≥30 78 0.24 55 0.25 1.03 (0.69–1.53) 0.886 
Visual impairment 
Yes 103 0.32 123 0.55 3.16 (2.21–4.53) <0.001 
No 219 0.68 102 0.44 0.32 (0.22–0.45) <0.001 
Allergies 
Yes 40 0.12 40 0.18 1.56 (0.97–2.51) 0.068 
No 282 0.88 185 0.82 0.64 (0.40–1.03) 0.068 
Heart and vascular diseases 
Yes 177 0.55 130 0.58 1.14 (0.81–1.62) 0.441 
No 145 0.45 95 0.42 0.87 (0.62–1.23) 0.441 
OR, odds ratio; 95% CI, 95% confidence interval; p-values < 0.05 along with corresponding ORs are in bold. 
2.3. The c.–441G>A and the g.61564299G>T Polymorphisms of the FEN1 Gene and  
KC/FECD Occurrence 
The genotype and allele distributions of the c.–441G>A and the g.61564299G>T polymorphisms of 
the FEN1 gene in KC patients and controls are presented in Table 4. We observed a significant  
(p < 0.05) difference in the frequency distributions of genotypes of the g.61564299G>T polymorphism 
between the cases and controls. The presence of the T/T genotype was associated with an increased 
occurrence of KC. We did not find any association between genotypes/alleles of the c.–441G>A 
polymorphism and KC occurrence. 
Table 4. Distribution of genotypes and alleles of the c.–441G>A (rs174538) and the 
g.61564299G>T (rs4246215) polymorphisms of the FEN1 gene and the odds ratio (OR) 
with the 95% confidence interval (95% CI) in patients with keratoconus (KC) and controls. 
Polymorphism 
Genotype/Allele 
Controls (n = 322) KC (n = 279) Crude OR  
(95% CI) 
p 
Adjusted OR a 
(95% CI) 
p 
Number Frequency Number Frequency 
c.-441G>A 
A/A 17 0.05 17 0.06 1.16 (0.58–2.33) 0.667 1.28 (0.38–4.25) 0.689 
A/G 178 0.55 161 0.58 1.10 (0.80–1.52) 0.550 0.64 (0.40–1.05) 0.079 
G/G 127 0.39 101 0.36 0.87 (0.63–1.21) 0.414 1.52 (0.92–2.51) 0.104 
χ2 = 0.745; p = 0.6891 
A 212 0.33 195 0.35 1.13 (0.85–1.49) 0.390 0.75 (0.49–1.16) 0.200 
G 432 0.67 363 0.65 0.88 (0.67–1.17) 0.390 1.33 (0.86–2.06) 0.200 
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Table 4. Cont. 
Polymorphism 
Genotype/Allele 
Controls (n = 322) KC (n = 279) Crude OR  
(95% CI) 
p 
Adjusted OR a 
(95% CI) 
p 
Number Frequency Number Frequency 
g.61564299G>T 
G/G 149 0.46 106 0.38 0.71 (0.51–0.99) 0.042 0.96 (0.59–1.55) 0.860 
G/T 157 0.49 141 0.51 1.07 (0.78–1.48) 0.663 0.74 (0.46–1.20) 0.219 
T/T 16 0.05 32 0.11 2.48 (1.33–4.62) 0.004 5.15 (1.69–15.67) 0.004 
χ2 = 10.420; p = 0.0055 
G 455 0.71 353 0.63 0.68 (0.52–0.88) 0.004 0.76 (0.51–1.14) 0.185 
T 189 0.29 205 0.37 1.47 (1.13–1.91) 0.004 1.31 (0.88–1.96) 0.185 
p < 0.05 along with corresponding ORs are in bold; OR a adjusted for sex, age, co-occurrence of visual 
impairment, allergies, heart and vascular diseases and family history for KC. 
Table 5 presents the genotype and allele distributions of the c.–441G>A and the g.61564299G>T 
polymorphisms of the FEN1 gene in FECD patients and controls. We detected a significant (p < 0.05) 
difference in the frequency distributions of genotypes of the c.–441G>A polymorphism between the 
cases and controls. We showed an association between the presence of the T/T genotype of the 
g.61564299G>T polymorphism and an increase of the occurrence of FECD. We did not detect any 
correlation between genotypes/alleles of the c.–441G>A polymorphism and FECD occurrence. 
Table 5. Distribution of genotypes and alleles of the c.–441G>A (rs174538) and the 
g.61564299G>T (rs4246215) polymorphisms of the FEN1 gene and odds ratio (OR) with 
95% confidence interval (95% CI) in patients with Fuchs endothelial corneal dystrophy 
(FECD) and controls. 
Polymorphism  
Genotype/Allele 
Controls (n = 322) FECD (n = 225) Crude OR  
(95% CI) 
p 
Adjusted OR a 
(95% CI) 
p 
Number Frequency Number Frequency 
c.-441G>A 
A/A 17 0.05 12 0.05 1.01 (0.47–2.16) 0.978 1.20 (0.47–3.07) 0.706 
A/G 178 0.55 101 0.45 0.66 (0.47–0.93) 0.017 0.73 (0.48–1.10) 0.134 
G/G 127 0.39 112 0.50 1.52 (1.08–2.15) 0.017 1.33 (0.88–2.00) 0.179 
χ2 = 6.043; p = 0.0487 
A 212 0.33 125 0.28 0.74 (0.55–0.99) 0.044 0.83 (0.58–1.19) 0.312 
G 432 0.67 325 0.72 1.35 (1.01–1.82) 0.044 1.20 (0.84–1.71) 0.312 
g.61564299G>T 
G/G 149 0.46 106 0.47 1.03 (0.73–1.45) 0.847 0.96 (0.64–1.45) 0.859 
G/T 157 0.49 98 0.44 0.81 (0.57–1.14) 0.230 0.84 (0.55–1.26) 0.349 
T/T 16 0.05 21 0.09 1.97 (1.01–3.86) 0.049 2.25 (1.01–5.00) 0.047 
χ2 = 4.519; p = 0.1040 
G 455 0.71 310 0.69 0.91 (0.69–1.20) 0.508 0.85 (0.61–1.18) 0.329 
T 189 0.29 140 0.31 1.10 (0.83–1.45) 0.508 1.18 (0.85–1.64) 0.329 
 17 0.05       
p-values < 0.05 along with corresponding ORs are in bold; OR a adjusted for the co-occurrence of visual 
impairment, sex, age and family history for FECD. 
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The observed genotypes frequencies of the g.61564299G>T polymorphism did not deviate 
statistically significantly from these expected from the Hardy–Weinberg equilibrium, among KC and 
FECD patients (p > 0.05, data not shown). 
2.4. Haplotypes and KC/FECD Occurrence 
The association between KC/FECD and haplotypes of the c.–441G>A and the g.61564299G>T 
polymorphisms of the FEN1 gene was also assessed (Table 6). The presence of the GG haplotype was 
associated with increased and the GT haplotype with decreased occurrence of KC. We also detected an 
association between the AG haplotype and an increased occurrence of FECD. 
Table 6. Distribution of haplotypes of c.–441G>A (rs174538) and the g.61564299G>T 
(rs4246215) polymorphisms of the FEN1 gene and the odds ratio (OR) with the 95% 
confidence interval (95% CI) in patients with KC and FECD and controls. 
Haplotype 
Controls (n = 322) KC (n = 279) OR  
(95% CI) 
p 
FECD (n = 225) OR  
(95% CI) 
p 
Number Frequency Number Frequency Number Frequency 
AG 221 0.17 178 0.16 
1.09  
(0.88–1.35) 
0.427 110 0.12 
1.49  
(1.16–1.90) 
0.002 
AT 203 0.16 212 0.19 
0.79  
(0.65–0.99) 
0.036 140 0.16 
1.02  
(0.80–1.28) 
0.897 
GG 689 0.53 528 0.47 
1.28  
(1.10–1.50) 
0.002 510 0.57 
0.88  
(0.74–1.04) 
0.142 
GT 175 0.14 198 0.18 
0.73  
(0.58–0.91) 
0.051 140 0.16 
0.85  
(0.67–1.09) 
0.197 
p < 0.05 along with corresponding ORs are in bold. 
3. Discussion 
KC and FECD are eye diseases with a complex aetiology. The pathogenesis of these diseases is  
still poorly understood, although several studies try to clarify mechanisms of their development  
and progression. To date, multiple genes were identified as possibly implicated in KC and  
FECD [9,28,40–42]. In addition, various environmental factors, including chronic eye rubbing, 
wearing hard contact lenses and atopy of the eye, seem to have a role in the pathogenesis of  
these diseases [3,26,43]. 
The analysis of the relationship between some clinical, environmental and life style parameters and 
the occurrence of KC and FECD independent from genotypes in our study indicated a significant 
influence of a positive family history of KC and FECD. A strong correlation between KC/FECD 
family history and KC/FECD occurrence was found in several other studies [9,44]. A significant 
association between visual impairment, allergic, heart and vascular disease and KC was also detected. 
In the present work, we demonstrated a significant correlation between visual impairment and FECD 
occurrence. These results confirm results obtained in other laboratories [43,45–47]. 
A growing body of evidence indicates that oxidative stress plays an important role in the 
pathogenesis of KC and FECD [3,48–51]. This hypothesis is supported by an excess of ROS and 
disturbance in the level of transcripts and/or activities of antioxidant enzymes in KC and FECD 
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corneas compared to controls [3,48,49,51,52]. In addition, increased levels of oxidant-induced DNA 
damage in KC and FECD corneas was found, especially in mitochondrial DNA (mtDNA) [2,3,53]. 
An increased levels of oxidative DNA damage in KC and FECD corneas may be associated with 
functional changes in DNA repair genes that result in a decrease in the DNA repair capacity. Human 
cells have multiple DNA repair pathways, including nucleotide excision repair (NER), base-excision 
repair (BER), mismatch repair (MMR), homologous recombination repair (HRR) and non-homologous 
end joining (NHEJ). 
FEN1 is an important nuclease, which is involved in the repair of non-bulky DNA lesions, 
including multiple oxidative DNA damage. FEN1 removes bifurcated DNA structures with displaced 
5'-single-stranded DNA flaps during long-patch BER [54]. Moreover, this enzyme has 5' to 3' 
exonuclease and gap-dependent endonuclease activities, owing to its being implicated in the 
maturation of Okazaki fragments and the rescue of stalled replication forks [55]. FEN1 is also  
involved in other major DNA metabolic pathways, including resolution of tri-nucleotide repeat  
sequence-derived secondary structures, maintenance of telomere stability and apoptotic fragmentation 
of DNA [56]. FEN1 was also detected in the mitochondria, where it participates in mitochondrial DNA 
(mtDNA) replication and repair. As FEN1 has an important role in numerous DNA metabolic 
pathways, this enzyme is essential to maintain genome integrity. The functional deficiency of FEN1 
may lead to severe genomic instability and an increased mutation rate, contributing to susceptibility to 
a number of genetic diseases [57]. It was found that the c.–441G>A SNP located in the FEN1 
promoter causes changes in promoter activity, whereas the g.61564299G>T SNP is associated with 
different levels of FEN1 RNA expression [58]. The c.–441G>A and the g.61564299G>T 
polymorphisms of FEN1 are significantly associated with reduced FEN1 expression and increased 
DNA damage. It was found that these SNPs increase the risk of developing lung cancer in  
Chinese populations. 
To our knowledge, this is the first study investigating the association of the c.–441G>A and the 
g.61564299G>T polymorphisms of the FEN1 gene on the occurrence of KC and FECD. We found a 
significant association between the g.61564299G>T polymorphism of the FEN1 gene and KC risk. 
The occurrence of KC was significantly increased in patients carrying the T/T genotype, suggesting 
that the g.61564299G>T polymorphism may play a role in KC. However, we observed no association 
between the c.–441G>A polymorphism of the FEN1 gene polymorphism and the risk of KC. The T/T 
genotype of the g.61564299G>T polymorphism was also positively correlated with increased 
occurrence of FECD. We did not find any association between the c.–441G>A polymorphism of the 
FEN1 gene and FECD. 
4. Experimental Section  
4.1. Study Population 
Our study was carried out on 279 patients with KC, 255 patients with FECD and 322 individuals 
with FECD/KC exclusion (controls). They were enrolled in the Department of Ophthalmology, 
Medical University of Warsaw (Warsaw, Poland). Medical history was obtained from all patients, and 
none of them had any genetic disease. 
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The diagnosis of KC was based on clinical signs and pachymetric and topographical parameters on 
Orbscan and Topographic Modeling System (TMS) corneal topography examinations [4,59,60]. The 
map patterns were carefully interpreted manually in all cases. All subjects underwent ophthalmic 
examination, including intraocular pressure, slit lamp examination, best-corrected visual acuity, fundus 
examination, Orbscan corneal topographical and pachymetrical maps (Orbscan IIz, Bausch & Lomb, 
Rochester, NY, USA) and corneal topography (TMS4, Tomey, Nagoya, Japan). 
The diagnosis of FECD was based on clinical signs on the slit lamp examination, including the 
occurrence of endothelial guttae and corneal oedema. Diagnoses were confirmed by the presence of 
specific lesions, polymegathism and pleomorphism of the endothelial cells in in vivo confocal 
microscopy (IVCM) examination [61,62]. Patients underwent ophthalmic examination, including 
intraocular pressure, best-corrected visual acuity, fundus examination, slit lamp examination, IVCM 
and anterior segment optical coherence tomography (AS-OCT), including pachymetry maps. The  
AS-OCT was performed by Swept Source Anterior Segment Casia OCT (Tomey, Nagoya, Japan). The 
IVCM was performed by a white light scanning slit confocal microscopy system (ConfoScan 3 or 
ConfoScan 4, Nidek Techologies, Padova, Italy). 
The control subjects showed no clinical evidence of FECD/KC and had healthy corneal 
endothelium on IVCM and normal corneal pachymetry and topography. 
Each individual donated five millilitres of venous blood to EDTA-containing tubes, which were 
stored at −20 °C. 
This study was performed according to the tenets of the Bioethics Committee of the Medical 
University of Warsaw. All patients gave written informed consent and were interviewed using a 
structural questionnaire to obtain information on demographic data and potential risk factors for  
KC and FECD. The data collected included age, BMI, co-occurrence of visual impairment (hyperopia, 
astigmatism, myopia), heart or vascular diseases, allergy, family history among first degree relatives 
for KC or FECD and lifestyle habits, including smoking. Smoking was categorized as never smokers 
and ever smokers. The characteristics of all subjects are presented in Table 1. 
4.2. Selection of SNPs and Primer Design 
The c.–441G>A and g.61564299G>T polymorphisms of the FEN1 gene were chosen from the 
public domain of the National Centre for Biotechnology Information at http://www.ncbi.nlm. 
nih.gov/snp. These SNPs possess a minor allele frequency (MAF) 0.321 and 0.628 in the Caucasian 
population, respectively (submitter population ID: HapMap-CEU for both http://www.ncbi.nlm.nih. 
gov/snp). The primers were designed using the published nucleotide sequence in the ENSEMBL 
database (gene ID ENSG00000168496) and Primer3 software (http://frodo.wi.mit.edu/). 
4.3. Genotyping 
Total genomic DNA was isolated from peripheral blood leukocytes using the commercially 
available AxyPrep™ Blood Genomic DNA Miniprep kit (Axygen Biosciences, Union City, CA, 
USA), according to the manufacturer’s protocol. The purity and concentration of DNA were 
determined by taking the optical density (OD) of the samples at 260 and 280 nm, and the DNA was 
stored in TE buffer (5 mM Tris-HCl, 0.1 mM EDTA, pH 8.5), at −20 °C until use. 
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The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was 
used to genotype these polymorphisms of the FEN1 gene. A PCR assay was carried out in a final 
reaction volume of 10 μL. The reaction mixture contained 25 ng of genomic DNA, 1× KAPA Taq 
Ready Mix containing KapaTaq DNA polymerase (0.025 U/μL), reaction buffer with MgCl2, 0.2 mM 
each dNTP (Kapa Biosystems, Woburn, MA, USA) and 0.25 μM each primer (Sigma-Aldrich,  
St. Louis, MO, USA). 
The following sequencing primers were used to detect the c.–441G>A SNP: the sense 5'-GGAGGT 
TCCAGGAGCGTCTA-3' and antisense 5'-TTCTCCACCGCTTGTCCC-3'. The PCR profile comprised 
a 5-min initial denaturation at 95 °C, 34 cycles of denaturation at 95 °C for 30 s, at 65 °C annealing for 
30 s, extension for 60 s at 72 °C, and the final extension for 5 min at 72 °C. The amplified DNA 
fragments of 321 bp in length, containing the polymorphic site, were digested with 1.5 U of SalI 
restriction endonuclease (New England Biolabs, Ipswich, UK) in a final volume of 15 μL for 16 h at 
37 °C. Individual genotypes were assigned according to the size of the products: the G/G genotype 
corresponds to 321 bp; the A/A genotype 169 and 152 bp and the A/G genotype 321, 169 and 152 bp 
(Figure 1). 
Figure 1. Restriction fragment length polymorphism analysis of the FEN1 c.–441G>A 
(rs174538) polymorphism. Genotypes are indicated in the upper part of the picture.  
Lane M is a GeneRuler™ 100-bp marker ladder. 
 
The g.61564299G>T polymorphism was genotyped in a fragment of the FEN1 gene with the 
following primer sequences: forward 5'-TATGTCAGGCTCAAACCAC-3' and reverse 5'-CAGCCA 
GTAATCAGTCACAA-3'. The PCR assay was performed under the following conditions: initial 
denaturation step at 95 °C for 5 min, 34 cycles at 95 °C for 30 s, 30 s at 66 °C annealing temperature, 
60 s extension at 72 °C and the final extension step for 5 min at 72 °C. The PCR amplification product 
of 343 bp, containing the polymorphic site, was digested with 1.5 U of BsmAI restriction endonuclease 
(New England Biolabs, Ipswich, UK) in a final volume of 15 μL for 16 h at 37 °C. DNA fragments of 
sizes 236 and 107 bp indicate the G/G genotype, with 343, 236, and 107 being the G/T genotype and 
fragments of 343 bp the T/T genotype (Figure 2). 
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Figure 2. Restriction fragment length polymorphism analyses of the g.61564299G>T 
(rs4246215) polymorphism of FEN1. Genotypes are indicated in the upper part of the 
picture. Lane M is a ΦX174 DNA/BsuRI Marker ladder. 
 
Digested products were evaluated on an 8% polyacrylamide gel. GeneRuler™ 100 bp (Fermentas, 
Hanover, MD, USA) or the ΦX174 DNA/BsuRI Marker (Fermentas, Hanover, MD, USA) was used as 
a molecular mass marker. Electrophoresis was carried out at 5 V/cm in TBE buffer and analysed under 
UV light following ethidium bromide staining. All PCR amplifications were conducted in a C1000 
Thermal Cycler (Bio-Rad Laboratories, Hercules, CA, USA). Positive and negative (no template) 
controls were included in all sets. The accuracy of the genotyping was evaluated by performing 
duplicate analysis of 10% of samples, and the results were 100% concordant. 
4.4. Statistical Analysis 
To compare the distributions of demographic variables and selected risk factors between patients 
and controls, the chi-square (χ2) test was used. The Hardy–Weinberg equilibrium was checked using 
the χ2 test to compare the observed and expected genotype frequencies. The χ2 analysis was also used 
to test the significance of the differences between distributions of genotypes and alleles in KC/FECD 
patients and controls. The association between case-control status and each polymorphism, measured 
by the odds ratio (OR) and its corresponding 95% confidence interval (CI), was estimated using an 
unconditional multiple logistic regression model, both with and without adjustment for age, sex,  
co-occurrence of visual impairment, allergies, heart or vascular diseases and family status of 
KC/FECD. Statistical analysis was performed using the SigmaPlot software, version 11.0 (Systat 
Software, Inc., San Jose, CA, USA). 
5. Conclusions 
Our results suggest that the g.61564299G>T polymorphism of the FEN1 gene may be associated 
with susceptibility to KC and FECD and be considered as markers in these diseases. 
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